The study looked at 83 patients having a posterior SI joint fusion with the LinQ implant, according to a March 20 news release. The study found statistically significant improvement in visual analog scale sores. The mean improvement was 43.3 at 12 months compared to baseline.
The LinQ implant also showed a strong safety profile with five adverse events and no implant-related adverse events in the patients.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
